Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion

Journal of Neuro-Oncology

Volumn 41, Issue 1, 1999, Pages 9-20

  Bredel, Markus ^a   Pollack, Ian F ^a,b   Freund, John M ^a   Rusnak, James ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Apoptosis; Astrocytoma; Glioma; Growth inhibition; Protein kinase C; Signal transduction; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; DNA FRAGMENT; PROTEIN KINASE C; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; ENZYME INHIBITION; GEL ELECTROPHORESIS; GLIOMA CELL; HUMAN; HUMAN CELL;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; COLORING AGENTS; ELECTROPHORESIS, AGAR GEL; ENZYME INHIBITORS; GLIOMA; HUMANS; IN SITU NICK-END LABELING; PROTEIN KINASE C; STAUROSPORINE; TIME FACTORS; TRYPAN BLUE; TUMOR CELLS, CULTURED;

EID: 0032961049     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006047025425     Document Type: Article

References (56)

1. Pollack IF, Kawecki S: Patterns of growth factor, growth factor receptor, and second messenger expression in pediatric brain tumors. J Neurosurg 80: 400A, 1994.
2. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 73: 98-105, 1990.
3. Baltuch GH, Dooley NP, Rostworowski KM, Villemure JG, Yong VW: Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. J Neuro-Oncol 24: 241-250, 1995.
4. Baltuch GH, Dooley NP, Villemure JG, Yong VW: Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 22: 264-271, 1995.
5. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717-724, 1992.
6. Couldwell WT, Hinton DR, Law RE: Protein kinase C and growth regulation in malignant gliomas. Neurosurgery 35: 1184-1186, 1994.
7. Couldwell WT, Uhm J, Antel JP, Yong VW: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29: 880-887, 1991.
8. Yong VW: Proliferation of human and mouse astrocytes in vitro: signaling through the protein kinase C pathway. J Neurol Sci 111: 92-103, 1992.
9. Ahmad S, Mineta T, Martuza RL, Glazer RI: Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35: 904-909, 1994.
10. Baltuch GH, Couldwell WT, Villemure J-G, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993.
11. Baltuch GH, Dooley NP, Couldwell WT, Yong VW: Staurosporine differentially inhibits glioma versus non-glioma cell lines. J Neuro-Oncol 16: 141-147, 1993.
12. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW: Inhibition of growth of established human glioma cell lines by modulators of the protein kinase C system. J Neurosurg 73: 594-600, 1990.
13. Kuratsu J, Sato K, Saitoh Y, Takeshima H, Morioka M, Ushio Y: The mechanism of growth-regulation of glioma cells by trapidil. J Neuro-Oncol 23: 201-206, 1995.
14. Pollack IF, Kawecki S, Lazo JS: Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84: 1024-1032, 1996.
15. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Effects Of tainoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990.
16. Vertosick FT Jr, Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30: 897-903, 1992.
17. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. J Antibiotics 42: 571-576, 1989.
18. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081-2086, 1993.
19. Denko N, Giaccia B, Peters B, Stamato TD: An asymmetric field inversion gel electrophoresis method for the separation of large DNA molecules. Anal Biochem 178: 172-176, 1989.
20. Rusnak JM, Calmels TPG, Hoyt DG, Kondo Y, Yalowich JC, Lazo JS: Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells. Molec Pharmacol 49: 1-9, 1996.
21. Schmitz G, et al.: Nonradioactive labeling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Anal Biochem 192: 222-231, 1991.
22. Brown DG, Sun X-M, Cohen GM: Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem 268: 3037-3039, 1993.
23. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M: Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
24. 2+-dependent cleavage of DNA into kilobase pair fragments is responsible for the initial degradiation of DNA in apoptosis. J Biol Chem 269: 14857-14860, 1994.
25. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-613, 1992.
26. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75: 284-293, 1991.
27. Gillaspy GE, Mapstone TB, Samols D, Goldthwait DA: Transcriptional patterns of growth factors and protooncogenes in human glioblastomas and normal glial cells. Cancer Lett 65: 55-60, 1992.
28. Werner MH, Humphrey PA, Bigner DD, Bigner SH: Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against EGF receptor on four glioma cell lines. Acta Neuropathol 77: 196-201.
29. Westphal M, Brunken M, Rhode E, Herrmann H-D: Growth factors in cultured human glioma cells: different effects of FGF, EGF, PDGF. Canc Lett 38: 283-296, 1988.
30. Fields AP, Tyler G, Kraft AS, May WS: Role of nuclear protein kinase C in the mitogenic response to platelet-derived growth factor. J Cell Science 96: 107-114, 1990.
31. Susa M, Olivier AR, Fabbro D, Thomas G: EGF induces biphasic S6 kinase activation: late phase is protein kinase C-dependent and contributes to mitogenicity. Cell 57: 817-824, 1989.
32. Aaronson SA: Growth factors and cancer. Science 254: 1146-1153, 1991.
33. Pollack IF, Kawecki S: Tamoxifen: The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr Neurosurg 22: 281-288, 1995.
34. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994.
35. Evans VG: Multiple pathways to apoptosis. Cell Biol int 17: 461-476, 1993.
36. Zhang W, Law RE, Hinton DR, Su Y, Couldwell WT: Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Cancer Letters 96: 31-35, 1995.
37. Chen CY, Faller DV: Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 11: 1487-1498, 1995.
38. Dive C, Evans CA, Chapman RC, Owen-Lynch PJ, Whetton AD: Signal transduction events for the suppression of apoptosis. Br J Cancer 71: 5, 1994.
39. Evans CA, Lord JM, Owen-Lynch PJ, Johnson G, Dive C, Whetton AD: Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. J Cell Science 108: 2591-2598, 1995.
40. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 269: 26865-26870, 1994.
41. Zhu WH, Loh TT: Differential effects of phorbol ester on apoptosis in HL-60 promyelocytic leukemia cells. Biochem Pharmacol 51: 1229-1236, 1996.
42. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707-1714, 1994.
43. Zong Z, Fujikawa-Yamamoto K, Tanino M, Teraoka K, Yamagishi H, Odashima S: Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity. Biochem Biophys Res Commun 219: 480-485, 1996.
44. Denmeade SR, Isaacs JT: Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 3: 303-309, 1996.
45. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to caiphostin C, a specific protein kinase C inhibitor. J Neurosurg 83: 1008-1016, 1995.
46. Iwasaki K, Toms SA, Barnett GH, Estes ML, Gupta MK, Barna BP: Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human gliobiastoma cells. Cancer Immunol Immunother 40: 228-234, 1995.
47. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888-4892, 1991.
48. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2: 791-797, 1996.
49. Hill DL, Tillery KF, Rose LM, Posey CF: Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Canc Chemother Pharmacol 35: 89-92, 1994.
50. Mizuno K, Noda K, Ueda Y, Hanaki H, Saido TC, Ikuta T, Kuroki T, Tamaoki T, Hirai S-i, Osada S-i, Ohno S: UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett 359: 259-261, 1995.
51. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Molec Pharmacol 45: 1207-1214, 1994.
52. Wang Q, Worland PJ, Clark IL, Carlson BA, Sausville EA: Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth & Differentiation 6: 927-936, 1995.
53. Wyllie AH, Morris RG, Smith AC, Dunlop D: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67-77, 1984.
54. Falcieri E, Martelli AM, Bareggi R, Cataldi A, Cocco L: The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem Biophys Res Commun 193: 19-25, 1993.
55. Ormerod MG, O'Neill CF, Robertson D, Harrap KR: Cisplatin induces apoptosis in a human ovarian cell line without concomitant internucleosomal degradiation of DNA. Exp Cell Res 211: 231-237, 1994.
56. Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 10: 587-597, 1996.